Scalpel Weekly News

Week of: February 03, 2014

IN THE NEWS


Embolization System Has Incorrect Instructions; Class I Recall

The FDA has classified the recently initiated medical device correction notice related to the TRUFILL n-BCA Liquid Embolic System as a Class I recall. Click title to continue reading...


 
MEDICAL ALERTS


Acute Illness Associated with Use of Pest Strips

Dichlorvos-impregnated resin strips (DDVP pest strips) are among the few organophosphate products still available for indoor residential use. The residential uses for most other organophosphate products, including most DDVP products, were canceled because they posed unreasonable risks to children. Click title to continue reading...



Pro ArthMax Contains Several Hidden Drug Ingredients

The FDA is advising consumers not to purchase or use Pro ArthMax, a product promoted and sold as a dietary supplement for joint, muscle and arthritic pain. Click title to continue reading...



Ranbaxy India Facility Added to US Drug Ban

The FDA notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug products. Click title to continue reading...


  CASE ALERTS


Continuous Treatment Doctrine, No Further Care, and Limitations

A patient’s doctor referred him to an urologist. The man did not return to the doctor to complain about or seek treatment for the same condition. Subsequently, the man was diagnosed with colon cancer. Click title to continue reading...



Communications When Defendant Employs Plaintiff's Nonparty Physician

A man was admitted to the hospital where he underwent lung surgery. While there he developed sepsis resulting in the loss of both of his legs below the knee and both of his hands above the wrist. The man sued the hospital for negligent postoperative care. The complaint identified two doctors as physicians whose conduct gave rise to the lawsuit, but he did not name those doctors as defendants. Click title to continue reading...



Orthopedic Clinics Fined for Reimported Drugs

Two orthopedic clinics will pay a combined $1.85 million to resolve state and federal False Claims Act allegations that they knowingly billed state and federal health care programs for reimported osteoarthritis medications, known as viscosupplements. Click title to continue reading...